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Abstract 
Recent focus on Precision medicine (PM) has led to a flurry of 
research activities across the developed world. But how can 
understaffed and underfunded health care systems in the US 
and elsewhere evolve to adapt PM to address pressing 
healthcare needs? We offer guidance on a wide range of 
sources of healthcare data / knowledge sources as well as 
other infrastructure / tools that could inform PM initiatives, 
and may serve as low hanging fruit easily adapted on the 
incremental pathway towards a PM based healthcare system. 
Using these resources and tools, we propose an incremental 
adoption pathway to inform implementers working in 
underserved communities around the world on how they 
should position themselves to gradually embrace the concepts 
of PM with minimal interruption to existing care delivery. 
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Introduction 
The need to offer providers a more complete picture of an 
individuals' health has led to the advent of precision medicine 
(PM), which is defined as an emerging approach to optimize 
clinical decision-making by taking individual variability in 
genes, environment and lifestyle into account [8]. By 
harnessing measurements from multiple modalities such as 
clinical and genomic evaluations, environmental exposures, 
behavioral patterns, and many others, we can develop a far 
more comprehensive view of the patient’s health status and its 
trajectory over time. 
Despite the recent emergence of the PM initiative, its core 
underlying principals have been known for decades [20], and 
manifested over the years in various forms such as 
personalized medicine [12] and the learning healthcare system 
[6]. Further, PM inspired activities such as the delivery of 
patient specific allergy alerts [1] and tailored immunization 
guidance [11] have been routinely used for many decades. A 
notable difference between these and more recent PM 
initiatives is the intensified focus on so-called “-omics”, which 
includes the study of a body of information such as the 
genome, proteome, metabolome (metabolites), transcriptome 
(RNA transcripts), autoantibody profiles, etc., [13] made 
possible by the sequencing of the human genome [21] and 
rapid advances in high-throughput laboratory technologies and 
systems approaches across the fields of computer and 
biological sciences [7]. 
While -omics based therapeutics have gained widespread 
publicity and demonstrate significant potential [19], there 
remain barriers to translating and broadly implementing these 
discoveries in the care delivery process. For example, -omics 
based PM therapeutics are expensive and resource-intensive 
activities that currently are ill-suited for large-scale clinical 
care [4; 10] because breakthroughs in many -omics based 
therapeutics will not be available for use until research and 
discovery activities progress over the next 5 - 10 years [15].  
By definition, the scope of PM is much larger than -omics. 
PM promises to provide a more complete picture of an 
individuals' health by capturing actionable information 
detailing individuals' health status and their socioeconomic 
context to inform provider decision-making. Thus, the core 
concepts of PM are relevant to modern medical care and 
beneficial for both developed and underserved settings. 
Examples of easily implementable low cost PM-based care 
that does not rely on -omics based treatment include 
identifying high-risk patients based on socioeconomic factors 
and detecting adverse drug events occurring among members 
of genetically similar groups. 
While -omics based PM initiatives are typically cost intense 
and thus, currently unsuitable for widespread use, the overall 
aims of PM are relevant and invaluable for healthcare 
delivery. Thus, all healthcare systems, even those of the 
underserved world, stand to learn from this approach. Recent 
focus on PM has led to a flurry of research activities across the 
developed world. But how can understaffed and underfunded 
health care systems in the US and elsewhere evolve to adapt 
PM to address pressing healthcare needs? Which PM based 
solutions are most suitable for use across underserved settings, 
if any? Also, which needs should be prioritized as 
implementers begin the thought process leading toward a PM 
based healthcare system?  
We advocate that PM is heavily dependent on leveraging both 
novel and existing data and knowledge sources to ensure the 
accessibility and availability of information surrounding an 
individual and their environment. Thus, not all PM based 
activities may be cost and resource intensive. In this paper, we 
offer guidance regarding the wide range of sources of 
healthcare data and knowledge, as well as other infrastructure 
and tools that could inform PM initiatives. Such elements may 
serve as low hanging fruit easily and incrementally adopted on 
a pathway towards a PM based healthcare system. Using these 
resources and tools, we propose a progressive adoption 
pathway to inform implementers across the underserved world 
on how they should position themselves to gradually 
incorporate the principles of PM with minimal interruption to 
existing healthcare delivery. 
Methods 
Based on findings of the Precision Medicine initiative cohort 
program [14] and seminal publications [3; 8; 18] we sought to 
identify data and knowledge sources that could be leveraged 
to support PM-based care delivery. However, these cannot 
operationalize PM based care without appropriate supporting 
systems and processes. Thus, we also identified a list of key 
infrastructural components that would enable the use of data 
and knowledge sources for delivering appropriate PM based 
care. 
Next, we sought to describe an incremental adoption pathway 
for underserved settings that seek to adopt PM initiatives by 
proposing when each of the aforementioned data, knowledge 
an infrastructure components should be integrated into exiting 
healthcare systems. We considered five criteria to evaluate 
where each component fit into our proposed adoption 
pathway:  
(1) The availability of robust technical tools / platforms for 
ready use (Availability): Are mature toolsets with 
demonstrated evidence of use available for adoption? 
(2) The level of provider and user education / training required 
for adoption (Workforce capacity): Does the tool/approach 
require specialist technical skills? How difficult is it to 
develop local capacity to manage and operate these systems? 
(3) The practicality of integrating it into the existing health 
ecosystem and workflows (Integration to healthcare): Can the 
component be feasibly integrated into existing/emerging 
infrastructure? Will it lead to disruptions, and does it require 
significant behavior changes for use? 
(4) Cost burden/sustainability: How sustainable is care 
delivery using these new components?  
(5) Clinical impact: Does robust evidence indicate this 
element meaningfully improves clinical outcomes? 
We adopted the ThoughtWorks Technology Radar (TTR) [26] 
to present our incremental PM adoption pathway. The TTR is 
a living document prepared by the ThoughtWorks 
Corporation, a leading software development company, to 
assess the risks and rewards of existing and nascent 
technologies, and the strategic importance of each of these for 
their organization at a specific point in time. TTR presents a 
concise overview of techniques, tools, platforms/languages 
and frameworks (four quadrants of a circle), and recommend 
their strategic importance to technology organizations by 
allocating each of these to one of four bins - adopt, trial, asses 
and hold (four concentric rings of a circle). In adopting TTR 
for our own needs, we modified it as follows: 
(a) Rather than the four quadrants presented in the TTR, we 
propose three slices (data, knowledge and infrastructure) 
(b) Rather than the four rings presented in the TTR, we 
propose three: Adopt (highly significant components that 
must be adopted immediately), Aspire (components that 
should be focused on only after the adopt phase is competed) 
and Hold (components that should be held off for a future date 
where further advances are made).  
As our model is intended to represent a static snapshot the 
current state of PM-based research, and not serve as a 'living 
document', we will forgo TTR's ‘new’, ‘moved’ ‘or no 
change’ icons to indicate how the influence of each 
component has shifted over time. 
Results 
Various components and their adaption 
We identified the following data components (Table 1), 
knowledge components (Table 2) and infrastructure (Table 3) 
as nessesary for enabling PM based care systems.
Table 1. Data types, examples and sources
  
Table 2. Knowledge types, description and sources
Id Knowledge type Description ‘Exemplar’ or ‘Typical’ Sources 
11 Drug-drug 
interactions 
Information on how a drug affects the activity 
of another when administered together. 
(11) Drug knowledge bases, such as Medscape and 
Drugbank. 
Id Data type Examples ‘Exemplar’ or ‘Typical’ Sources 
Source 1: Clinical, demographic and behavioral data 
1 Patient demographics 
and contact information 
Birthdate, gender, race, sexuality, address, educational 
status, occupation 
(1A) EHR systems; (1B) Patient registries 
(PR) 
2 Behavioral and lifestyle 
measures 
Physical activity levels, smoking/tobacco/alcohol use, 
assessment of other risk factors  
(2A) EHR systems; (2B) Smart phones, 
wearable and home based devices  
3 Sensor-based data Cardiac rate and rhythm monitoring, respiratory rate, 
physical activity etc. 
(3) Smart phones, wearable and home 
based devices  
4 Structured clinical data  Medication, problem and diagnosis lists, vital signs, 
lab results, family health history measures etc.  
(4A) EHR systems; (4B) Non -omics based 
Laboratory Information Systems (LIS) 
5 Unstructured clinical 
data  
Narrative free text data/reports, EKG/EEG waveform 
data, radiology/medical imaging 
(5A) EHR systems; (5B) Picture Archiving 
and Communication Systems (PACS)  
6 -Omics data derived 
from bio-specimens  
 
Genomics, proteomics, metabolites, cell-free DNA, 
single cell studies, infectious exposures, standard 
clinical chemistries, histopathology etc.  
(6) External/ancillary Laboratory 
Information Systems that support -omics 
testing 
Source 2: Geospatial socio-economic, environmental and public health data 
7 Socioeconomic data Education, unemployment and crime rates, access to 
transportation, social services, health resources etc. 
(7) Various state, private/not-for-profit, 
and advocacy organizations 
8 Public health data Health insurance coverage, disease rates, life 
expectancy, obesity rates etc. 
(8) Various state and private/not-for-profit 
monitoring organizations  
9 Healthcare resource 
data 
Data on healthcare providers and facilities (9A) Provider registries; (9B) Health 
facility registries 
Source 3: Other  
10 Data obtained from 
social media 
Behavioral data, over the counter medication 
purchases, food / drug consumption etc. 
(10A) Facebook, twitter, other social 
media; (10B) Pharmacy billing data 
12 Drug-gene 
interactions 
Information on how a patient’s genetic 
metabolic affects their ability to clear a drug. 
(12) The Drug Gene Interaction Database (DGIdb) 
[27]; PharmGKB [25] 
13 Allergen databases 
 
Information on protein allergens and a 
patient's susceptibility  
(13) Online databases such as allergome.org, 
allergen.org etc. [17] 
14 Genomics 
knowledge bases 
Information on human genes, genetic 
phenotypes and disorders, and relationships 
between phenotype and genotype. 
(14) Tools such as Online Mendelian Inheritance in 
Man® (OMIM) [2], HGVbaseG2P [24] 
15 Public Health 
Genomics 
The use of genomic discoveries to improve 
healthcare and disease prevention 
(15) Public Health Genomics Knowledge Base [28] 
Table 3. Infrastructure resources 
Id Infrastructure 
component 
 Description  
16 EHR systems (16) An electronic version of patients’ current and past medical condition that may include all 
key administrative clinical data relevant to a patients care under a particular provider, including 
demographics, progress notes, problems, medications, diagnosis etc.  
17 Picture Archiving and 
Communication Systems 
(PACS)  
(17) A medical imaging tool that provides storage and access to images from medical imaging 
technologies such as ultrasound (US), magnetic resonance (MR), Nuclear Medicine imaging, 
positron emission tomography (PET), endoscopy (ES), digital radiography (DR), radiography 
(CR) etc.  
18 Laboratory Information 
Systems (LIS) and tools 
(18A) Traditional LIS (18B) LIS that support -omics based testing (18C) -Omics based testing 
equipment 
19 Patient, provider and 
facility registries  
(19A) Patient registries (19B) Provider / health worker registries (19C) Facility registries 
20 Disease registries (20) Registries used to track clinical care and outcomes of a defined patient population suffering 
from one or more chronic diseases such as diabetes, coronary artery disease, cancer or asthma. 
21 Medical terminologies  (21) Various clinical terminologies for reporting diseases (ICD), SNOMED, laboratory data 
(LOINC) etc. 
22 Messaging standards (22) Various standards introduced to exchange electronic health data across multiple systems. 
Examples: the Health Level 7 (HL7) family of standards and the DICOM standard. 
23 Health Information 
Exchange (HIE) 
(23) A well rounded HIE would consist of many components listed above, such as point of care 
applications (EHR systems), various registries and a Shared Health Record (SHR) etc. 
24 Biobank systems (24) A biorepository that stores biological samples for use in laboratory based (genomics and 
traditional) testing. 
 
The information presented in Tables 1, 2 and 3 were fit into a 
PM technology radar (Figure 1) based on the five evaluation 
criteria presented above. The PM technology radar is 
comprised of three slices (data, knowledge and infrastructure) 
and three concentric circles (adopt, aspire and hold). 
Description of the PM Technology radar 
The Data slice: As step 1 we recommend collecting various 
unstructured and structured clinical data from EHR, PACS 
and LIS systems that may already co-exist within a healthcare 
facility. As step 2, we recommend investigating and 
integrating other healthcare data such as various registries and 
other geospatial information sources that may already exist 
outside the borders of the immediate healthcare facility. This 
facilitates the use of non-clinical socioeconomic and public 
health data that could be used to paint a better picture of 
patients’ overall health. Step 3 consists of -omics data and 
personal data sources such as social networks and smart 
phones, wearable and home based devices. We also note that 
some data types such as patient demographics and contact 
information may be obtained from multiple sources that 
belong to different stages. In such an event, we recommend 
that data sources are adopted incrementally over each stage, 
with patient demographics captured from EHR systems in 
stage 1, and gradually supplemented with registry data during 
stage 2.  
The knowledge slice: We recommend adopting drug-drug 
interaction information as step 1. All other knowledge sources 
are based on -omics, and thus, should be held off for step 3. 
 
Figure 1. PM technology radar 
The infrastructure slice: As step 1, we advocate adopting core 
health IT components such as EHR, PACS and LIS systems, 
together with medical terminology/vocabularies and 
messaging standards for collecting clinical data. Step 2 
consists of incorporating different health infrastructure 
components that together, form a robust health ecosystem; 
ideally a fully functional health information exchange. We 
recommend that -omics based infrastructure components be 
placed on hold, to be enabled together with genomic based 
data and knowledge sources after appropriate advanced are 
made in the field.  
Discussion 
Enabling PM based care systems can be seen as two distinct 
but related challenges: (a) optimizing the use of existing 
sources of readily available data and knowledge spread across 
clinical, socioeconomic, and public health spheres, and (b) the 
integration of -omics based therapeutics and other data 
obtained from smart devices and additional sources outside of 
the traditional healthcare delivery domain.  
A fundamental requirement for all PM-based systems is the 
efficient management and use of structured information to 
inform providers’ view of patients’ health status. Thus, basic 
EHR systems that are widely used within underserved settings 
can serve as an initial stepping-stone on the incremental 
pathway toward building a more complete PM based 
healthcare system. To ensure comprehensive adoption of PM-
based systems, readily obtainable clinical and behavioral data 
must also be sustainably captured and appropriate 
infrastructure components must be built to ensure that this 
data, together with additional sources of knowledge, are 
available for actionable use.  
In evaluating the PM technology radar, it is evident that our 
selection of priorities for each step matches a specific pattern; 
the collection of data, knowledge, and infrastructure defined 
as step 1 (adopt) implies that the first step in enabling PM 
based care delivery lies in consolidating standardized data 
collection within a healthcare facility. As per figure 1, it is 
also evident that a significant portion of infrastructure 
resources should be implemented during the early stages of 
the process, as terminology and messaging standards are 
crucial to ensure standardized data collection.  
The components assigned to step 2 (aspire) characterize 
expansion of data collection to resources that may lie beyond 
traditional disconnected healthcare facilities and towards a 
greater Health Information Exchange (HIE) spreading across a 
larger demographic area and resources. Adopting an HIE 
represents significant investment. However, many tools and 
platforms that enable HIE-based infrastructure have been in 
existence for years, and are available free of charge [9]. There 
is also significant value in shifting towards an HIE as these 
components can contribute to, and inform many other needs 
beyond PM based care delivery. In comparison, resources 
identified as step 3 (hold) represent a consolidation of -omics 
and other resources that have the potential to significantly 
impact healthcare delivery, but are too immature and/or 
expensive for adoption at current time.  
The PM technology radar also indicates that for underserved 
settings, early efforts should focus on using PM based 
initiatives to improve more common care delivery needs such 
as identifying patients at higher risk, better clinical decision 
support and medication adherence, as opposed to introducing 
new treatment processes for specific and less common 
diseases. 
While strategies for adopting resources defined under step 1 
are increasingly well understood, step 2 may not be as simple, 
and would require significant buy in and policy changes. Our 
approach includes significant emphasis on realizing a 
concordant HIE. However, this may be restricted by national 
or regional scale policies or law. For example, U.S. legislation 
bans creating a unique national patient identifier that could be 
used to effectively identify patients across the healthcare eco-
system. 
Our reasons to delegate -omics based therapeutics as 'hold' for 
underserved settings are manifold, and based on practical, 
financial and policy based limitations rather than disagreement 
on the benefits of PM. Currently, genomic testing is available 
for approximately 2,000 clinical conditions in the U.S., and 
the number of available diagnostic tests is increasing 
exponentially [18]. However, genetics are only responsible for 
20% of an individual’s overall health status. Healthy 
behaviors (50%), environment (20%) and access to care (10%) 
pose significant impact on health, and are also relatively 
cheaper and easier to adopt [5]. Further, existing health 
information systems may not be geared to manage -omics 
based care. Research suggests that EHRs have poor support 
for online test ordering and provide limited decision support 
for genetic testing, interpretation of test results, and potential 
impact of results on patients and their families [22]. There is 
also significant need to develop, deploy, and adopt data 
standards to ensure data privacy, security, and integrity in 
managing PM based care delivery across these systems [23].  
-Omics based treatment also raises significant questions 
regarding patient confidentiality and health payer rights and 
policies. In the U.S., these concerns led to the signing of the 
Genetic Information Nondiscrimination Act (GINA) [16]. 
However, other countries have been slow to follow. Given 
these considerations, and that projection that -omics based PM 
initiatives focused on discovery of disease risk factors, 
pharmacogenomics, disease biomarker discovery, loss-of-
function mutations, new classification of diseases and clinical 
trials of targeted therapies are not expected to be realized over 
the next 5 to 10 years [15], we recommend that these 
components are placed on hold.  
The use of smart devices for fitness and monitoring purposes 
is enjoying significantly greater interest and adoption in 
comparison to -omics based resources. However, we have 
assigned it to step 3 (hold) as; (a) smart devices do not 
contribute as significantly as other components and resources. 
These data often may also be collected via EHR systems or 
questionnaires, thus reducing their value; (b) despite 
tremendous interest, smart devices have not matured 
adequately to be robustly integrated with healthcare 
infrastructure, and may lead to security vulnerabilities. 
However, we acknowledge that smart devices present 
considerable potential, and may be moved to step 2 shortly. 
Conclusions 
The advent of PM represents the continuation of research 
principals that have manifested in many forms over recent 
decades. Despite overemphasis on -omics based theraputics, 
effective PM based care delivery also involves the efficient 
use of existing sources of clinical and public health data that 
are less expensive and easily integrated into existing 
healthcare infrastructure, and thus serve as 'low hanging fruits' 
for managing PM based care delivery. We present a PM 
technology radar that informs implementers on how they 
could gradually shift towards enabling better PM based care 
delivery.  
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